Search results
Showing 2296 to 2310 of 2577 results for methods
Evidence-based recommendations on autologous chondrocyte implantation in people with symptomatic articular cartilage defects of the knee.
Discontinued Reference number: GID-TA10495
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
In development Reference number: GID-TA11228 Expected publication date: TBC
Lumella point-of-care test for assessing pre-eclampsia risk (MIB287)
NICE has developed a medtech innovation briefing (MIB) on Lumella point-of-care test for assessing pre-eclampsia risk .
NICE has developed a medtech innovation briefing (MIB) on InterDry for intertrigo .
QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)
NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .
Axonics sacral neuromodulation system for faecal incontinence (MIB259)
NICE has developed a medtech innovation briefing (MIB) on Axonics sacral neuromodulation system for faecal incontinence .
Immunoscore for predicting risk of colon cancer relapse (MIB269)
NICE has developed a medtech innovation briefing on Immunoscore for predicting risk of colon cancer relapse .
NICE has developed a medtech innovation briefing (MIB) on URO17 for detecting bladder cancer .
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
NaviCam for diagnosing gastrointestinal tract conditions (MIB104)
NICE has developed a medtech innovation briefing (MIB) on NaviCam for diagnosing gastrointestinal tract conditions .
Community pharmacies: promoting health and wellbeing (NG102)
This guideline covers how community pharmacies can help maintain and improve people’s physical and mental health and wellbeing, including people with a long-term condition. It aims to encourage more people to use community pharmacies by integrating them within existing health and care pathways and ensuring they offer standard services and a consistent approach. It requires a collaborative approach from individual pharmacies and their representatives, local authorities and other commissioners.
This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.
This guideline covers recognising and managing antisocial behaviour and conduct disorders in children and young people aged under 19. It aims to improve care by identifying children and young people who are at risk and when interventions can prevent conduct disorders from developing. The guideline also makes recommendations on communication, to help professionals build relationships with children and young people and involve them in their own care.